Spring Sleep’s most specific documented strength: clinical testing shows 90% of users experienced a notable reduction in nightly snoring, 78% saw reduced sleep apnea overall, and 89% of partners reported better sleep — from a device used only 20 minutes per day while awake. The eXciteOSA is FDA-cleared for primary snoring and mild obstructive sleep apnea — a specific US regulatory clearance that distinguishes this from consumer wellness gadgets. Spring Sleep’s Scientific Advisory Board includes ENT specialists from Cleveland Clinic, Stanford Health System, and Massachusetts General Hospital — institutional medical credibility documented at the brand’s October 2025 AAO-HNSF presentation. HonestBrandReviews confirms “clinical studies published between 2018 and 2023 report reductions in AHI, ODI, and objective snoring measures in mild OSA patients.” The core proposition: for people with mild-to-moderate OSA who won’t tolerate CPAP or find mandibular advancement devices uncomfortable overnight, Spring Sleep offers 20 minutes of daytime electrical stimulation — tolerable, portable, and clinically evidenced. The documented honest caveats: $1,650 upfront plus $150 every 90 days for replacement mouthpieces makes this one of the most expensive consumer sleep health investments available. It is specifically for mild-to-moderate OSA — not for severe cases. And the subscription mouthpiece replacement cost is ongoing.